Search Results
News Release
NIH researchers have identified a treatment that significantly decreases the risk of stroke in children with a rare genetic disease called Deficiency of Adenosine Deaminase Type 2 (DADA2).
… Anti-inflammatory drug halts strokes in children with rare disease …
Staff
Dr. Heidi Parker is an Associate Investigator in the Comparative Genetics Section of the Cancer Genetics and Comparative Genomics Branch, NHGRI.
… Investigator in the Comparative Genetics Section of the Cancer Genetics and Comparative Genomics Branch at the … laboratory of Dr. Elaine Ostrander at the Fred Hutchinson Cancer Research Center, established the first classification … genomic loci involved in complex morphological traits and cancer susceptibility. Dr. Parker has capitalized on the …
Talking Glossary
Un carcinógeno es una sustancia, organismo o agente capaz de causar cáncer.
News Release
The U.S. Food and Drug Administration has approved the first treatment for progeria, a rare and fatal pediatric disease, characterized by dramatic, rapid aging beginning in childhood.
… What The U.S. Food and Drug Administration has approved the first treatment for … of a mouse model, and the demonstration that this drug class could provide benefit. Progeria, also known as … The U.S. Food and Drug Administration has approved the first treatment for …
Talking Glossary
BRCA1 y BRCA2 son los dos primeros genes que se identificaron como asociados a tipos hereditarios del cáncer de mama y de ovario. Las personas con mutaciones en BRCA1 o BRCA2 tienen un riesgo mucho más alto de desarrollar cáncer de mama, de ovario u otros tipos de cáncer en comparación con las personas que no tienen mutaciones en estos genes.
Talking Glossary
Un oncogén es un gen que sufrió una mutación y que tiene el potencial de causar cáncer.
For Patients and Families
Neglected diseases are conditions that inflict severe health burdens on the world's poorest people.
… on the world's poorest people and are often overlooked by drug developers or by others instrumental in drug access. … are said to be neglected if they are often overlooked by drug developers or by others instrumental in drug access, such as government officials, public health …
Event
Annual scientific lecture honoring NHGRI's founding scientific director, Jeffrey M. Trent, Ph.D.
… MIT and Harvard, will present the lecture, Perspectives on Cancer Precision Medicine . Dr. Golub is a world leader in using genomics tools to understand the basis of cancer. He also pioneered the development of new cell-based approaches to drug discovery for cancer and other diseases. Golub is also …
Clinical Studies
The IDENTIFY Study is a study exploring how prenatal blood test results for the baby might also detect cancer in the mother.
… asymptomatic person.   I’ve already been diagnosed with cancer. Can I still participate? Yes. If you were diagnosed with cancer after receiving an abnormal or non-reportable NIPT … participants for up to 5 years. If you are diagnosed with cancer, we will collect information from you, but you will …